Soluble fibrin inhibitory peptides and uses thereof

Number of patents in Portfolio can not be more than 2000

United States of America Patent

PATENT NO 9777054
SERIAL NO

11508815

Stats

ATTORNEY / AGENT: (SPONSORED)

Importance

Loading Importance Indicators... loading....

Abstract

See full text

The present invention demonstrated that soluble fibrin binds to both Mac-1 and ICAM-1-expressing cells and inhibited adherence of these cells and immune cytotoxicity, thus inducing immune suppression in cancer. Additionally, the present invention also demonstrated that soluble fibrin enhanced metastasis in an in vivo model. Furthermore, the present invention demonstrated the utility of specific peptides that block binding of soluble fibrin to these cells as therapeutic agents in cancer progression and metastasis. It is further contemplated that these peptides can also be used to treat other diseases such as cardiovascular disease, arthritis and in many inflammatory responses where there is increased levels of soluble fibrin.

Loading the Abstract Image... loading....

First Claim

See full text

Family

Loading Family data... loading....

Patent Owner(s)

  • ENSION INC.

International Classification(s)

Inventor(s)

Inventor Name Address # of filed Patents Total Citations
Biggerstaff, John Oak Ridge, US 1 0
Weidow, Brandy Knoxville, US 1 0

Cited Art Landscape

Load Citation

Patent Citation Ranking

Forward Cite Landscape

Load Citation

Maintenance Fees

Fee Large entity fee small entity fee micro entity fee due date
7.5 Year Payment $3600.00 $1800.00 $900.00 Apr 3, 2025
11.5 Year Payment $7400.00 $3700.00 $1850.00 Apr 3, 2029
Fee Large entity fee small entity fee micro entity fee
Surcharge - 7.5 year - Late payment within 6 months $160.00 $80.00 $40.00
Surcharge - 11.5 year - Late payment within 6 months $160.00 $80.00 $40.00
Surcharge after expiration - Late payment is unavoidable $700.00 $350.00 $175.00
Surcharge after expiration - Late payment is unintentional $1,640.00 $820.00 $410.00